for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

FibroGen Inc

FGEN.O

Latest Trade

40.02USD

Change

-1.31(-3.17%)

Volume

377,663

Today's Range

39.84

 - 

41.40

52 Week Range

22.65

 - 

51.56

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
41.33
Open
41.33
Volume
377,663
3M AVG Volume
15.84
Today's High
41.40
Today's Low
39.84
52 Week High
51.56
52 Week Low
22.65
Shares Out (MIL)
91.01
Market Cap (MIL)
3,642.25
Forward P/E
-27.09
Dividend (Yield %)
--

Next Event

Q4 2020 FibroGen Inc Earnings Release

Latest Developments

More

Fibrogen Posts Q3 EPS $0.36

Fibrogen Reports Second Quarter 2020 Financial Results

Fibrogen Says On July 8, Units And Astrazeneca Entered Into An Amendment To Amended And Restated License, Development And Commercialization Agreement

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About FibroGen Inc

FibroGen, Inc. is a biopharmaceutical company committed to discovering, developing and commercializing a pipeline of first-in-class therapeutics. The Company applies its capabilities in hypoxia-inducible factor (HIF) and connective tissue growth factor (CTGF) biology to advance innovative medicines for the treatment of unmet needs. The Company is currently developing and commercializing roxadustat, an oral small molecule inhibitor of HIF prolyl hydroxylase activity, for anemia associated with chronic kidney disease (CKD). Roxadustat is also in clinical development for anemia associated with myelodysplastic syndromes (MDS) and for chemotherapy-induced anemia (CIA). Pamrevlumab, an anti-CTGF human monoclonal antibody, is in clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), locally advanced unresectable pancreatic cancer (LAPC), Duchenne muscular dystrophy (DMD), and coronavirus (COVID-19).

Industry

Business Services

Contact Info

409 Illinois St

SAN FRANCISCO, CA

94158-2509

United States

+1.415.9781200

http://www.fibrogen.com

Executive Leadership

James A. Schoeneck

Chairman of the Board

Enrique A. Conterno

Chief Executive Officer, Director

Pat Cotroneo

Chief Financial Officer

Christine L. Chung

Senior Vice President, China Operations

Elias Kouchakji

Senior Vice President, Clinical Development, Drug Safety and Pharmacovigilance

Key Stats

2.20 mean rating - 10 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.1K

2018

0.2K

2019

0.3K

2020(E)

0.2K
EPS (USD)

2017

-1.730

2018

-1.030

2019

-0.890

2020(E)

-1.526
Price To Earnings (TTM)
--
Price To Sales (TTM)
30.53
Price To Book (MRQ)
8.05
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
13.16
LT Debt To Equity (MRQ)
10.44
Return on Investment (TTM)
-31.30
Return on Equity (TTM)
-26.82

Latest News

Latest News

BRIEF-Fibrogen Says On July 8, Units And Astrazeneca Entered Into An Amendment To Amended And Restated License, Development And Commercialization Agreement

* FIBROGEN - ON JULY 8, UNITS AND ASTRAZENECA ENTERED INTO AN AMENDMENT TO AMENDED AND RESTATED LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT

BRIEF-FibroGen Announces First Patient Enrolled In Pamrevlumab Clinical Trial For Acute Covid-19

* FIBROGEN ANNOUNCES FIRST PATIENT ENROLLED IN PAMREVLUMAB CLINICAL TRIAL IN PATIENTS HOSPITALIZED IN U.S. WITH ACUTE COVID-19

BRIEF-Fibrogen Announces New Roxadustat Data Presented At 2020 Era-Edta Virtual Congress

* FIBROGEN ANNOUNCES NEW ROXADUSTAT DATA PRESENTED AT 2020 ERA-EDTA VIRTUAL CONGRESS

BRIEF-Fibrogen Says First Patient Enrolled In COVID-19 Trial In Italy

* FIBROGEN ANNOUNCES FIRST PATIENT ENROLLED IN PAMREVLUMAB CLINICAL TRIAL IN PATIENTS HOSPITALIZED IN ITALY WITH SEVERE COVID-19 Source text for Eikon: Further company coverage:

BRIEF-Fibrogen Says UK High Court Of Justice Has Held Certain Patents Relating To Methods Of Using HIF-PHIs To Be Invalid

* FIBROGEN - UK HIGH COURT OF JUSTICE HAS HELD CERTAIN PATENTS RELATING TO METHODS OF USING HIF-PHIS TO BE INVALID

BRIEF-Fibrogen Inc Signs Agreement For Bulk Manufacture/Supply Of Roxadustat

* FIBROGEN INC - AGREEMENT WITH SHANGHAI SYNTHEALL PHARMACEUTICAL CO LTD, STA PHARMACEUTICAL HONG KONG LIMITED FOR BULK MANUFACTURE/SUPPLY OF ROXADUSTAT

China first to approve AstraZeneca, FibroGen anaemia drug

China has become the first country to approve a new anaemia drug from AstraZeneca and FibroGen, well before decisions by regulators in the United States or Europe.

BRIEF-FibroGen Reports Q1 Loss Per Share $0.50

* Q1 EARNINGS PER SHARE VIEW $-0.51 -- THOMSON REUTERS I/B/E/S

BRIEF-Fibrogen Inc CEO's 2017 Compensation Was $7.1 Million

* FIBROGEN INC SAYS CEO THOMAS B. NEFF'S 2017 TOTAL COMPENSATION WAS $7.1 MILLION VERSUS $5.2 MILLION IN 2016 – SEC FILING Source text (https://bit.ly/2Hpk39x) Further company coverage:

BRIEF-FibroGen Gets FDA Fast Track Designation For Its Pancreatic Cancer Treatment

* UPDATE - FIBROGEN GRANTED FAST TRACK DESIGNATION BY U.S. FDA FOR PAMREVLUMAB TREATMENT OF PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE PANCREATIC CANCER

BRIEF-Fibrogen Granted Fast Track Designation By U.S. FDA For Pamrevlumab Treatment Of Patients

* FIBROGEN GRANTED FAST TRACK DESIGNATION BY U.S. FDA FOR PAMREVLUMAB TREATMENT OF PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE PANCREATIC CANCER Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

BRIEF-FibroGen Q4 Loss Per Share $0.27

* FIBROGEN REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up